Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders

Otros/as autores/as

Institut Català de la Salut

[Kuwana M] Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; Scleroderma/Myositis Center of Excellence (SMCE) Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, Japan. [Gil-Vila A, Selva-O'Callaghan A] Unitat de Malalties Autoimmunes Sistèmiques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2022-04-25T14:50:54Z

2022-04-25T14:50:54Z

2021-01-01



Resumen

Autoanticuerpos; Trastornos reumáticos autoinmunes; Enfermedad pulmonar intersticial


Autoanticossos; Trastorns reumàtics autoimmunes; Malaltia pulmonar intersticial


Autoantibodies; Autoimmune rheumatic disorders; Interstitial lung disease


Interstitial lung disease (ILD) has been recognized as a frequent manifestation associated with a substantial morbidity and mortality burden in patients with autoimmune rheumatic disorders. Serum autoantibodies are considered good biomarkers for identifying several subsets or specific phenotypes of ILD involvement in these patients. This review features the role of several autoantibodies as a diagnostic and prognostic biomarker linked to the presence ILD and specific ILD phenotypes in autoimmune rheumatic disorders. The case of the diverse antisynthetase antibodies in the antisynthease syndrome or the anti-melanoma differentiation-associated 5 protein (MDA5) antibodies as a marker of a severe condition such as rapidly progressive ILD in patients with clinically amyopathic dermatomyositis are some of the associations herein reported in the group of myositis spectrum disorders. Specific autoantibodies such as the well-known anti-topoisomerase I (anti-Scl70) or the anti-Th/To, anti-U11/U12 ribonucleoprotein, and anti-eukaryotic initiation factor 2B (eIF2B) antibodies seems to be specifically linked to ILD in patients with systemic sclerosis. Overlap syndromes between systemic sclerosis and myositis, also have good ILD biomarkers, which are the anti-PM/Scl and anti-Ku autoantibodies. Lastly, other not so often reported disorders as being associated with ILD but recently most recognized as is the case of rheumatoid arthritis associated ILD or entities herein included in the miscellaneous disorders section, which include anti-neutrophil cytoplasmic antibody-associated interstitial lung disease, Sjögren’s syndrome or the mixed connective tissue disease, are also discussed.


The authors received no financial support for the research, authorship, and/or publication of this article.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

SAGE Publications

Documentos relacionados

Therapeutic Advances in Musculoskeletal Disease;13

https://doi.org/10.1177/1759720X211032457

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)